News

SBI Pharmaceuticals Co., Ltd., Tokyo, and TAGCyx biotechnologies Inc., Tokyo, announced entering into a research and develop collaboration to develop innovative products in the field of cancer treatment.

SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director, President: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., and Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japan Foundation for Cancer Research (Laboratory: Tokyo; Division Head: Shingo Dan) announce that the outcome from the mutual collaboration study was just published in Scientific Reports, an online journal of Nature.

SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1, hereby announces that SBI Pharmaceuticals has granted the comprehensive commercialization rights on the pharmaceuticals containing 5-ALA including “ALAGLIO Divided Granules 1.5g” in the territory of MENA *2 and India to neopharma Japan Co., Ltd. (Head office: Chiyoda-ku, Tokyo; Representative Director: Satofumi Kawata; “neopharma Japan”), a subsidiary of neopharma LLC *3, a company of the United Arab Emirates (UAE) engaged in production and marketing of pharmaceuticals.

SBI Pharmaceuticals Co., Ltd. Yamagata University, Faculty of Medicine SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., engaged in the research and development of pharmaceuticals, health foods and cosmetics using 5-ALA (5-Aminolevulinic acid) (*1) and Yamagata University, Faculty of Medicine (Campus: Yamagata-shi, Yamagata; […]

Chugai Pharmaceutical Co., Ltd. SBI Pharmaceuticals Co., Ltd. TOKYO, December 18, 2017 — Chugai Pharmaceutical Co., Ltd. (Head office: Tokyo; Chairman & CEO: Osamu Nagayama; “Chugai”) announced that it will launch the photodynamic diagnostic agent, “ALAGLIO® Divided Granules 1.5g” (“this Agent”) on December 19th. This Agent was developed by SBI Pharmaceuticals Co., Ltd., (Head office: […]

SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; “SBI Pharma”), a subsidiary of SBI Holdings, Inc., engaged in the research and development of medicines using 5-ALA (5-Aminolevulinic acid) (*1) and Chugai Pharmaceutical Co., Ltd. (Head office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama; “Chugai”) hereby announce that the manufacture and marketing approval of a photodynamic diagnostic agent, “ALAGLIO® Divided Granules 1.5g” (Generic name: Aminolevulinic acid hydrochloride; “this Agent”) has been obtained from the Ministry of Health, Labour and Welfare for the indication of diagnostic agent to visualize non-muscle invasive bladder cancer at the operation of its transurethral resection.

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)(*1), hereby announces that the resection of bladder cancer by using aminolevulinic acid hydrochloride (SPP-005) […]

SBI Pharmaceuticals Co., Ltd. Chugai Pharmaceutical Co., Ltd. TOKYO, March 13, 2017 — SBI Pharmaceuticals Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and President: Yoshitaka Kitao; “SBI Pharma”), a subsidiary of SBI Holdings, Inc., engaged in the research and development of medicines using 5-ALA* (5-Aminolevulinic acid), has entered a licensing agreement with Chugai Pharmaceutical […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. University of Oxford SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1 and the University of Oxford in the United […]

SBI Pharmaceuticals Co., Ltd SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1, hereby announces that SBI Pharmaceuticals has concluded the exclusive license agreement with Neopharma LLC. […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1, hereby announces that the research paper on the safety and usefulness […]

SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”), hereby announces that a patent has recently been registered in the United States of America for the treatment of influenza virus infection.

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*, hereby announces that a patent has recently been registered in the United States of America on the […]

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*, hereby announces that a patent has recently been registered in Japan for an agent […]

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”) (*1), hereby announces that a patent has recently been registered in Japan for the […]

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”) (*1), hereby announces that a patent has recently been registered in Japan for the […]

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”) is a subsidiary of SBI Holdings, Inc. that engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”) *1, hereby announces that a patent has recently been registered in Japan […]

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA)*, hereby announces that a patent has recently been registered in Japan for a photodynamic […]

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*, hereby announces that a patent has recently been registered in Japan for the treatment […]

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1, hereby announces that a patent has recently been registered in Japan for the treatment […]

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1, hereby announces that a patent has recently been registered in Japan for a photodynamic […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”) (*1) announced in Antimicrobial Agents and Chemotherapy published on October 21 […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1. We are pleased to inform you that a U. S. Patent […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*. We are pleased to inform that SBI Pharmaceuticals has received from […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. ReproCELL Inc. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)* and ReproCELL Inc. (Head office: Kohoku-ku, Yokohama, Kanagawa; Chief […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*. We are pleased to inform you that SBI Pharmaceuticals has obtained […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*. We are pleased to announce the launch of our new product, […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*. We are pleased to inform you that we at SBI Pharmaceuticals […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods, cosmetics and medical devices for diagnosis using 5-aminolevulinic acid (“5-ALA”)*. We are pleased to inform you that […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1. We are pleased to inform you that SBI Pharmaceuticals has obtained […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. Osaka City University SBI  Pharmaceuticals  Co.,  Ltd.  (Head  office:  Minato-ku,  Tokyo;  Representative  Director  and  CEO:Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao) engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. Oxford University SBI Pharmaceuticals and the University of Oxford in the United Kingdom have signed an agreement for joint research to start a phase II clinical trial to assess the effectiveness of 5-aminolevulinic acid (“5-ALA”) (*1) in preventing a reduction in cardiac output (*2) after heart bypass surgery. […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”) is a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBIH”) engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”) is a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBIH”) engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. (SBIH), engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1. SBI Pharmaceuticals will begin selling the bicolor medical LED light […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”) is a subsidiary of SBI Holdings, Inc. engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1). It has been engaging in the 5-aminolevulinic acid (“5-ALA”) […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. ReproCELL Inc. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1 and ReproCELL Inc. (Head office: Kohoku-ku, Yokohama, Kanagawa; Chief […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. (SBIH), engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1. We are pleased to announce that the European Patent Office […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. (SBIH), engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1. We are pleased to announce that we have been received […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. The SBI Group is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”) at SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. We are pleased to inform you […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. The SBI Group is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”) at SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. (SBIH). We are pleased to inform […]

The University of Tokyo Tokyo Institute of Technology MRC National Institute for Medical Research SBI Pharmaceuticals Co., Ltd. The University of Tokyo, a national university (main campus: Bunkyo-ku, Tokyo; President: Junichi Hamada), Tokyo Institute of Technology, a national university (main campus: Meguro-ku, Tokyo; President: Yoshinao Mishima),MRC National Institute for Medical Research (London, U.K. Director: Jim […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We  are  pleased   to  inform  you  that  SBI  Pharmaceuticals   Co.,  Ltd.  (Head  office:  Minato-ku,   Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*), announces that today […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We  are  pleased   to  inform  you  that  SBI  Pharmaceuticals   Co.,  Ltd.  (Head   office:  Minato-ku,   Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*), announces that it […]

SBI Holdings, Inc. (TOKYO: 8473 / Hong Kong: 6488) SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; hereinafter “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., which researches and develops pharmaceuticals, health foods, and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has submitted a clinical trial application (CTA) to the […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinicacid (5-ALA) (*), announces that the in […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*), has entered into […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., which is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”), has obtained […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., which is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1), has reached a […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., which is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., has entered into a memorandum of understanding with Bahrain Mumtalakat Holding Company B.S.C. (c) (Head office: Manama, Bahrain; Chief […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1), has reached an […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has reached a […]

SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., which researches and develops pharmaceuticals, health foods, and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) announces that it has concluded a Basic Agreement to begin clinical research on diabetes in Bahrain with the Arabian Gulf University (AGU).

SBI Pharmaceuticals Co., Ltd SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, cosmetics and health foods using 5-aminolevulinic acid (5-ALA) officially acquired a permit of opening a representative office on October 9, 2012, as announced in […]

SBI Holdings, Inc. (TOKYO: 8473 / Hong Kong: 6488) SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., which researches and develops pharmaceuticals, health foods, and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has submitted an Investigational New Drug Application (IND) to the […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., which researches and develops pharmaceuticals, health foods, and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has submitted a clinical trial application (CTA) to the Medicines and Healthcare products Regulatory […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc. that conducts research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) announced that SBI Pharmaceuticals obtained the Product License of healthy supplement on […]

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, cosmetics and health foods using 5-aminolevulinic acid (5-ALA), opens a representative office in Manama, the capital of Bahrain. As announced in the press release […]

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., is engaged in research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA). SBI Pharmaceuticals hereby announces that a new executive officer was appointed effective September […]

SBI Pharmaceuticals Co., Ltd SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), an affiliate company of SBI Holdings, Inc. , is engaged in research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA). SBI Pharmaceuticals hereby announces that a new director was elected and […]

SBI Holdings, Inc. (TOKYO: 8473 / Hong Kong: 6488) SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”) ,affiliate company of SBI Holdings, Inc. ,is engaged in research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA). SBI Pharmaceuticals and Nobelpharma […]

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Holdings, Inc. (“SBIH”) conducts research and development on cosmetics, health foods and pharmaceuticals using 5-aminolevulinic acid (5-ALA) at its subsidiary SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative: Yoshitaka Kitao; “SBI Pharmaceuticals”). In relation to this, The University of Hawaii at Manoa Group has recently published […]

Tokyo, April 24, 2012－SBI Pharmaceuticals Co., Ltd., announced that they had obtained Marketing Authorization of their products containing 5-ALA (*1) from The Kingdom of Bahrain Ministry of Health. SBI Pharmaceuticals signed a Memorandum of Understanding with the Government of The Kingdom of Bahrain for intensive collaboration of R&D and distribution of 5-ALA in Bahrain and […]

SBI Holdings, Inc. (TOKYO: 8473 / Hong Kong: 6488) It is hereby notified that SBI Pharmaceuticals Co., Ltd., the SBI Holdings, Inc. subsidiary engaged in the research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA) (*1) (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; hereafter called “SBI Pharmaceuticals”) reached […]

SBI Holdings, Inc. (TOKYO: 8473 / Hong Kong: 6488) SBI ALApromo Co., Ltd., (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc., that conducts research and development of cosmetics, health foods and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, hereby announces that it has obtained First-class Marketing Authorization […]

SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, has succeeded in the detection of peritoneal dissemination of gastric cancer using ALA in […]

SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods and pharmaceuticals using 5-aminolevulinic acid (ALA)*1 has succeeded in the detection of peritoneal dissemination of gastric cancer and lymph node […]

SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. which conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, has discovered that ALA has the effect of enhancing hyperthermia therapy, in joint research […]

SBI ALApromo Co., Ltd SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, has discovered in joint research with Nihon University that ALA has the effect of […]

SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1 has discovered that administration of ALA had the effect of controlling debilitation of cancer-bearing […]

SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1 has identified a factor that determines sensitivity to photodynamic therapy using ALA, with Tokyo […]

SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, has found that ALA, a natural amino acid, has a growth inhibiting effect on […]

SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc., that conducts the research and development of cosmetics, health foods and medicines containing 5-aminolevulinic acid (ALA) is pleased to announce that its research paper on the diagnosis and treatment […]

SBI Holdings, Inc. SBI ALApromo Co., Ltd. Nobelpharma Co., Ltd. SBI ALApromo Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc., that conducts the research and development of cosmetics, health foods and medicines containing 5-aminolevulinic acid (ALA) *1 and Nobelpharma Co., Ltd. (head office: […]

SBI Holdings, Inc. SBI ALApromo Co., Ltd. Nobelpharma Co., Ltd. SBI ALApromo Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc., that conducts the research and development of cosmetics, health foods and medicines containing 5-aminolevulinic acid (ALA)*1, has reached agreement in principle with Nobelpharma […]

SBI Holdings, Inc. SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc., that conducts the research and development of cosmetics, health foods and medicines containing 5-aminolevulinic acid (ALA)*1, is pleased to announce the appointment of Motowo Nakajima as […]

SBI ALApromo Co., Ltd. (Head office: Minato-ku, Tokyo; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. that researches, develops and markets cosmetics, health foods, and medicines using 5-aminolevulinic acid (ALA), and medac GmbH (Head office: Wedel, Germany; “medac”), have signed an agreement on forming a joint venture company aimed at joint development of medicines in Europe.

SBI Holdings, Inc. COSMO OIL Co., Ltd. SBI Holdings, Inc. (Head office: Roppongi, Minato-ku, Tokyo; Representative: Yoshitaka Kitao; “SBI Holdings”) and Cosmo Oil Co., Ltd. (Head office: Shibaura, Minato-ku, Tokyo; Representative: Yaichi Kimura; “Cosmo Oil”) have signed today a joint venture agreement for the purpose of jointly developing “5-aminolevulinic acid (5-ALA),” a type of amino […]

SBI Holdings, Inc. SBI Holdings, Inc. (“the Company”) has founded SBI ALApromo Co., Ltd. (“SBI ALApromo”), a preparatory company that develops and markets medicines, cosmetics, and health food containing amino acid “5-aminolevulinic acid” (5-ALA) as an active ingredient. “5-ALA” is a natural amino acid that might appear 3.6 billion years ago and some foods such […]